Organigram Global (OGI) Net Income towards Common Stockholders (2018 - 2026)
Organigram Global (OGI) posted quarterly Net Income towards Common Stockholders of $13.9 million for Q1 2026, down 52.94% year-on-year from $29.5 million in Q1 2025, and up 176.71% on a QoQ basis from $5.0 million in Q4 2025.
Organigram Global (OGI) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Net Income towards Common Stockholders for 7 consecutive years, with $13.9 million the latest figure, recorded in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 52.94% year-over-year to $13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.4 million (up 96.48% YoY) and the FY2025 annual result came in at $4.5 million, changed N/A from the prior year.
- Net Income towards Common Stockholders climbed to $13.9 million in Q1 2026 per OGI's latest filing, from $5.0 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for OGI reached as high as $29.5 million in Q1 2025 and fell as low as -$4.9 million in Q4 2024.
- A 3-year average of $10.9 million and a median of $9.5 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders surged 203.1% — and 2026, when it slumped 52.94%.
- Year by year, Net Income towards Common Stockholders stood at -$4.9 million in 2024, then soared by 203.1% to $5.0 million in 2025, then jumped by 176.71% to $13.9 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $13.9 million, $5.0 million, and $29.5 million for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.95 Bn | 88.09 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.20 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.35 Bn | 18.55 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.47 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Organigram Global | 120.26 Mn | 153.33 Mn | 28.97 Mn | 13.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.89 Mn |
| Dec 31, 2025 | 5.02 Mn |
| Mar 31, 2025 | 29.51 Mn |
| Dec 31, 2024 | -4.87 Mn |
| May 31, 2021 | -104.73 Mn |
| Feb 28, 2021 | 100.73 Mn |
| Nov 30, 2020 | -34.34 Mn |
| Aug 31, 2020 | -170.07 Mn |
| May 31, 2020 | -65.51 Mn |
| Feb 29, 2020 | -6.83 Mn |
| Nov 25, 2019 | 15.25 Mn |
| May 31, 2019 | -7.05 Mn |
| Nov 30, 2018 | -38,000.00 |
| May 31, 2018 | -1.27 Mn |